Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antiblastic agents and/or BCG: Evaluation of tolerance

Archivio Italiano di Urologia e Andrologia

Volumn 78, Issue 1, 2006, Pages 1-4

  Morabito, Francesco ^a,k   Rossi, Riccardo ^a   Graziano, Manuela Efrem ^a   Ferrando, Ugo ^a   Lancini, Vanessa ^b   Cretarola, Emidio ^b   Conti, Giario ^b   Luporini, Anna Chiara ^c   Muto, Giovanni ^d   Castelli, Emanuele ^d   D'Urso, Leonardo ^d   Razionale, Pasquale ^e   Lissoni, Giuseppe ^f   Simone, Maurizio ^g   Francesca, Francesco ^g   Sommariva, Monica ^h   Casu, Marilena ⁱ   Hurle, Rodolfo ^j  

^a MOLINETTE HOSPITAL   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

^c Istituto Clinico S Ambrogio   (Italy)

^d S GIOVANNI BOSCO HOSPITAL   (Italy)

^e Ospedale SS Benedetto e Gertrude   (Italy)

^f Div Urologia Ospedale Civile   (Italy)

^g SANTA CHIARA HOSPITAL   (Italy)

^h Ospedale G Fornaroli   (Italy)

ⁱ SAN GERARDO HOSPITAL   (Italy)

^j Humanitas Gavazzeni Hospital   (Italy)

^k NONE   (Italy)

more..

Author keywords

Bladder cancer; Gemcitabine; Intravesical chemotheraphy immunotherapy; Side effects; Tolerance

Indexed keywords

BCG VACCINE; GEMCITABINE;

ADULT; AGED; ARTICLE; ASTHENIA; BLADDER TUMOR; CANCER RECURRENCE; CHEMOTHERAPY; CONTROLLED STUDY; CYSTECTOMY; DISEASE COURSE; DRUG SAFETY; DYSGEUSIA; DYSURIA; EDEMA; ENDOSCOPIC SURGERY; FEMALE; HEMATURIA; HUMAN; HYPERTHERMIA; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALAISE; MALE; PELVIS PAIN SYNDROME; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCG VACCINE; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 33646709189     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Perabo FG, Muller SC. New agents in intravesical chemotherapy of superficial bladder cancer. Scand J Urol Nephrol. 2005; 39:108
2. Miyake H, Eto H, Hara I, et al. Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting dusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells. J Urol. 2004; 171:2477.
3. Zoli W, Ricotti L, Tesei A, et al. Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. Clin Cancer Res. 2004; 10:1500
4. Kilani RT, Tamimi Y, Karmali S, et al. Selective cytotoxicity of gemcitabine in bladder cancer cell lines. Anticancer Drugs 2002; 13:557
5. Nativ O, Dalal E, Laufer M, Sabo E, Aronson M. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer. Urology 2004; 64:845
6. Cozzi PJ, Bajorin DF, Tong W, et al. Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 1999; 5:2629
7. Matera M, Costantino G, Clementi G, Lempereur L, Vasta D, Vasquez E. Experimental study on the toxicity and the local and systemic tolerability of gemcitabine after topical treatment of the rabbit bladder. Oncol Rep 2004; 11:1145
8. Laufer M, Ramalingam S, Schoemberg MP, et al. Intravesical gemcitabine therapy for superficiale transitional cell carcinoma of the bladder: a phase 1 and pharmacokinetic study. J Clin Oncol 2003; 21:697
9. De Berardinis E, Antonini G, Peters GJ, et al. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study study with pharmacodynamic evaluation. BJU International 2004; 93:491
10. Wiljes JA, Van der Heijden AG, Vriesema JL, Peters GJ, Laan A, Schalken JA. Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 2004; 45:182
11. Palou J, Carcas A, Segarra J, et al. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies m patients with superficial bladder cancer. J Urol. 2004; 172:485
12. Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical Gemcitabine in Bacillus Calmette-Guerin-Refractory transitional cell carcinoma of the bladder. J Clin Oncol 2002; 20:3193
13. O'Donnell MA. Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. Urol Clin North Am 2005; 32:121
14. Doval DC, Sekhon JS, Gupta SK et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004; 90:1516
15. Castagneto B, Zai S, Marenco D, Bertetto O et al. Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment. Oncology 2004; 67:27
16. Gontero P, Casetta G, Maso G, Sogni F, Pretti G, Zitella A, Frea B, Tizzani A. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 2004; 46:339
17. Joudi FN, O'Donnell MA. Second-line intravesical therapy versus cystectomy for Bacille Calmette-Guerin (BCG) failures. Curr Opin Urol 2004; 14:271